Solid Tumors Clinical Trial
Official title:
An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours
Verified date | January 2020 |
Source | Servier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Co-selective inhibition of VEGFRs and FGFR has the potential benefit of blocking the two most
relevant players in tumor angiogenesis and simultaneously targeting proliferation in
FGF-driven tumors. Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2,
3 and FGFR1 showing strong anti-angiogenic and anti-tumor activity in preclinical models at
well-tolerated oral doses, with a favorable pharmacokinetic profile. These properties make it
an attractive candidate for development in humans.
This is an open-label, uncontrolled, non-randomized, PhaseI/IIa study and its primary
objective is to determine the Maximum Tolerated Dose (MTD) of Lucitanib administered orally,
once daily, on a continuous schedule over the initial 28-day cycle.
Secondary objectives are to determine the safety profile, pharmacokinetics, pharmacodynamics
and antitumour activity of Lucitanib, given as a single agent to adult patients with advanced
solid tumours.
The study consists of two phases, a dose escalation phase followed by a dose-expansion phase
at the identified Recommended Dose (RD). Eligible patients have histologically or
cytologically confirmed locally advanced or metastatic solid tumours, relapsed or refractory
to standard therapy. For the dose expansion, patients should have tumours bearing FGFR1 or
11q 12-14 amplification, assessed by FISH or CGH array, or "sensitive" to antiangiogenic
treatment. These latter are defined as patients who have relapsed after having experienced
stable disease (lasting at least six months) or partial response with prior treatment with an
approved antiangiogenic regimen or patients with tumour types known to be potentially
responsive to antiangiogenic agents but without such pretreatment if no antiangiogenic agents
were approved and/or available for that specific condition (e.g thyroid cancer, thymic
carcinoma).
Serial safety assessments, including evaluation of symptoms, physical examination and blood
and urine laboratory analyses are performed throughout the study. Cardiac functions and blood
pressure are monitored in consultation with a cardiologist. PK parameters are determined on
plasma samples collected during the first 4-week cycle and analyzed using a validated
LC-MS/MS method. Correlative studies include: (i) quantitative assessment of the effects of
E-3810 on tumor vasculature by DCE-MRI and DCE-US imaging; (ii) assay of angiogenesis
biomarkers i.e. soluble VEGFR2, VEGFR1, VEGF, bFGF, Collagen IV, FGF23 and PIGF(by ELISA) and
circulating endothelial and progenitors cells (CEC and CEP). Tumor response is based on
imaging according to RECIST; circulating tumor cells (CTC) are measured by the immunomagnetic
CellSearch method.
In patients with tumours bearing FGFR1 amplifications the efficacy of Lucitanib will be
formally tested according to a phase IIa design (one-stage Flaming design, H0=0.05, H1=0,30,
power 0,80.
Status | Completed |
Enrollment | 134 |
Est. completion date | May 4, 2017 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age = 18 years 2. Histologically or cytologically confirmed, locally advanced or metastatic solid tumour, relapsed or refractory to standard therapy. In addition, only for the dose-expansion phase: i) solid tumour bearingFGFR1 amplification and, if breast cancer, with at least one prior endocrine therapy in the metastatic setting if ER+, and at least one chemotherapy line otherwise or ii) solid tumour progressing after having experienced SD (lasting for at least six month) or PR as best response to prior treatment with an approved or investigational antiangiogenic drug (e.g.: sorafenib, sunitinib, bevacizumab) as a single agent or in a chemotherapy combination or iii) solid tumour potentially sensitive to antiangiogenic treatments provided no antiangiogenic agents are approved and\or available for that specific condition. 3. Life expectancy = 3 months 4. Full recovery (to Grade = 1) from any prior surgical procedure(s) and from reversible side effects of prior therapy for cancer including radiation therapy, chemotherapy, and immunotherapy 5. Adequate haematologic function (haemoglobin = 9 g/dL, absolute neutrophil count [ANC] = 1500/mL, platelets = 100,000/mL), adequate renal function (serum creatinine< 1.5 mg/dL or creatinine clearance > 40 mL/min), and adequate hepatic function (serum bilirubin = 1.5 x upper limit of normal (ULN) mg/dL, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 3 x ULN) 6. Eastern Co-operative Oncology Group (ECOG) performance status = 1 7. Negative serum pregnancy test at screening in women of childbearing potential 8. For men and women of child-bearing potential, use of a medically accepted method of contraception (abstinence, barrier method with spermicide, intrauterine device, or steroidal contraceptive for women and barrier method for men) for the duration of the study and for 60 days after participation in the study 9. Willingness and ability to give written informed consent and to comply with study procedures Exclusion Criteria: 1. Active central nervous system (CNS) metastases not controlled by prior surgery or radiotherapy and/or low dose steroids 2. Haematologic malignancies (including leukaemia of any form, lymphoma, and multiple myeloma) 3. Active second malignancy or history of another malignancy within 2 years, with the exception of non-melanoma skin cancers or carcinoma in situ (CIS) of the breast or cervix or controlled, superficial carcinoma of the bladder 4. Treatment with any anticancer agent within 3 weeks, including investigational agents, chemotherapy, immunotherapy, biologic or hormonal therapy, surgery or radiation therapy (6 weeks for nitrosoureas, mitomycin or bevacizumab); luteinizing hormone releasing hormone (LHRH) agonist for prostate and mitotane for adrenal carcinoma are allowed. 5. Significant cardiovascular disease or condition, including: - Congestive heart failure requiring therapy - Ventricular and/or supra-ventricular arrhythmia requiring therapy - Severe conduction disturbance (including QTc interval prolongation > 0.47 sec [corrected], history of severe arrhythmia, or history of familial arrhythmia [e.g., Wolff-Parkinson-White syndrome]) - Angina pectoris requiring therapy - Left ventricular ejection fraction (LVEF) < 50% evaluated by cardiac ultrasound (ECHO) or Multi Gated Acquisition Scan (MUGA) - Uncontrolled hypertension (defined as systolic blood pressure = 140 mm Hg and/or diastolic blood pressure = 90 mm Hg with optimized antihypertensive therapy) - Myocardial infarction (MI) within 6 months prior to administration of the first dose - > Class I cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria 6. Ongoing treatment with Warfarin 7. Unavoidable concomitant treatment with any drug known for potential risk of causing Torsades de Pointes (see list in Appendix 4) 8. Significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhoea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation 9. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, thyroid and adrenal gland 10. Serious/active bacterial, viral or fungal infection (including known active human immunodeficiency virus [HIV] infection) requiring systemic treatment 11. Concurrent severe or uncontrolled medical disease or organ system dysfunction which, in the opinion of the Investigators, would limit life expectancy to < 3 months, compromise the patient's safety, or interfere with evaluation of the safety of the investigational product 12. Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study procedures 13. Known hypersensitivity to gelatin or lactose monohydrate 14. Difficulty with swallowing 15. Pregnant or lactating women. |
Country | Name | City | State |
---|---|---|---|
France | Hopital Louis Pradel | Lyon | |
France | Institute Gustave Roussy | Villejuif | Paris |
Italy | European Institute of Oncology | Milano | |
Spain | Vall d' Hebron University Hospital | Barcellona |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherches Internationales Servier |
France, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) | First 4-week treatment cycle | ||
Primary | Objective response rate (CR and PR according to RECIST) and rate of non-progressive disease at 24 weeks | To be assessed only in patients with tumours bearing FGFR1 amplification. | Throughout the treatment period (tumor evaluation every 8 weeks) | |
Secondary | Pharmacokinetics following single and multiple dose administration | first 4-week treatment cycle | ||
Secondary | Tumor perfusion measured by DCE MRI and DCE-US | First 4-week treatment cycle | ||
Secondary | Circulating markers of angiogenesis: VEGFR2, VEGFR1, VEGF, Collagen IV, bFGF, CEC and CEP | First 4-week treatment cycle | ||
Secondary | Tumor response according to RECIST; CTC | Throughout the treatment period | ||
Secondary | Safety profile and dose limiting toxicities (DLT) | Troughout the treatment period | ||
Secondary | Free tumor circulating DNA | First 4-week treatment cycle |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |